Intratumor heterogeneity and branched evolution revealed by multiregion sequencing

New England Journal of Medicine

Volumn 366, Issue 10, 2012, Pages 883-892

  Gerlinger, Marco ^a,d   Rowan, Andrew J ^a   Horswell, Stuart ^a   Larkin, James ^b   Endesfelder, David ^a   Gronroos, Eva ^a   Martinez, Pierre ^a   Matthews, Nicholas ^a   Stewart, Aengus ^a   Tarpey, Patrick ^c   Varela, Ignacio ^c   Phillimore, Benjamin ^a   Begum, Sharmin ^a   McDonald, Neil Q ^a   Butler, Adam ^c   Jones, David ^c   Raine, Keiran ^c   Latimer, Calli ^c   Santos, Claudio R ^a   Nohadani, Mahrokh ^b   Eklund, Aron C ^f   Spencer Dene, Bradley ^a   Clark, Graham ^a   Pickering, Lisa ^b   Stamp, Gordon ^a,b   Gore, Martin ^b   Szallasi, Zoltan ^f,g   Downward, Julian ^a   Futreal, P Andrew ^c   Swanton, Charles ^a,e   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Royal Marsden Hospital Department of Medicine   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; S6 KINASE; TUMOR MARKER;

ALLELIC IMBALANCE; ANEUPLOIDY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CASE REPORT; CLEAR CELL CARCINOMA; CLONAL EVOLUTION; DISEASE ASSOCIATION; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXOME; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KDM5C GENE; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; LUNG METASTASIS; MAMMALIAN TARGET OF RAPAMYCIN GENE; MUTATIONAL ANALYSIS; NEPHRECTOMY; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; PTEN GENE; SEQUENCE ANALYSIS; SETD2 GENE; SOMATIC MUTATION; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU GENE;

EID: 84863393080     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1113205     Document Type: Article

References (30)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
2. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
3. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74. (Pubitemid 44571966)
4. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-42.
5. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-66.
6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
7. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-13.
8. Campbell PJ, Pleasance ED, Stephens PJ, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A 2008;105:13081-6.
9. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008;322:1377-80. (Pubitemid 352775249)
10. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100: 1014-8. (Pubitemid 34832631)
11. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25. (Pubitemid 41039112)
12. Inukai M, Toyooka S, Ito S, et al. Pres-ence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-8. (Pubitemid 44299146)
13. Lee AJ, Endesfelder D, Rowan AJ, et al. Chromosomal instability confers intrinsic multi-drug resistance. Cancer Res 2011;71:1858-70.
14. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010;103:1139-43.
15. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4.
16. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
17. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
18. Tao Y, Ruan J, Yeh SH, et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cellpopulation genetic analysis of wholegenome data. Proc Natl Acad Sci U S A 2011;108:12042-7.
19. Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with ultralong oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009;27:182-9.
20. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35. (Pubitemid 44862677)
21. Navin N, Krasnitz A, Rodgers L, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20:68-80.
22. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360-3.
23. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95.
24. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63.
25. Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5:379-85. (Pubitemid 47584475)
26. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6. (Pubitemid 38327529)
27. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9. (Pubitemid 33126820)
28. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70. (Pubitemid 32913522)
29. Poste G. Bring on the biomarkers. Nature 2011;469:156-7.
30. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.